Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis

NCT: NCT07178951 · RECRUITING

NCT IDNCT07178951
StatusRECRUITING
Start Date2026-09-09
Completion2027-03-30
SponsorFUSMobile Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.

Frequently Asked Questions

What is Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis?

Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis is a clinical trial registered under NCT07178951. Current status: RECRUITING.

What is the status of NCT07178951?

The current status of NCT07178951 (Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis) is: RECRUITING.

When did Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis start?

Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis started on 2026-09-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.